Date / Time: Thursday, November 5th at 12:00pm ET (1 Hour Webinar)
Join LMC Manna’s President, Research Karri Venn in an upcoming webinar hosted by SCRS that will be focusing on diversity within clinical trials, and how improvements can be made in future studies.
Diverse patients are currently underrepresented in clinical trials and the FDA is encouraging sponsors to prioritize meeting patient diversity targets in studies. Black Americans who make up 20% of U.S. multiple myeloma patients (who are also twice as likely to be diagnosed), only accounted for 4.5% of participants in multiple myeloma trials since 2003. The FDA launched guidance to have trial subjects reflect the patient population that will take the medication once approved, but that starts with increasing trust in clinical trials among diverse populations.
- Results from an Inato survey of over 250 clinical research sites and how diversity can be improved
- Tactical advice for how to include diverse patient populations in upcoming trials
- The latest FDA guidance on having trial subjects reflect the patient population taking the medication
To register for the webinar on November 5th, click here.
Looking forward to further learning together on how to improve diversity in clinical trials in Canada, the US, and beyond!